Form D · Pharmaceuticals
LianBio
Grand Cayman, E9 · CIK 0001831283
Offering snapshot reported Apr 5, 2021 · SEC filing
- Reported sold
- $3M Indefinite offering
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 5, 2021 | Initial | $2,999,977 | No comparison | Not reported | SEC filing |
| Nov 12, 2020 | Initial | $269,999,972 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-394673
Source: Form D, filed Apr 5, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Tassos Gianakakos | Director |
| Tom Anastasios Giannakakos | Director |
| Neil Kumar | Director |
| Bing Li | Director, Executive |
| Konstantin Poukalov | Director |
| Adam Leo Stone | Director |
| Debra Yu | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
C/O Ogier Global (Cayman) Limited 89 Nexus Way, Camana Bay
Grand Cayman, E9, KY1-9009
Grand Cayman, E9, KY1-9009